Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 2/20 | 0.50 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | TBXA2R | P21731 | 3/20 | 0.42 |
| ▸ | BLM | P54132 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | MME | P08473 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | SLC13A5 | Q86YT5 | 2/20 | 0.39 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.39 |
| ▸ | PPARD | Q03181 | 2/20 | 0.36 |
| ▸ | PPARA | Q07869 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7415791 | 0.84 | HIF1A (0.56) | CYP2C19HIF1ACYP2D6TSHRBLM | |
| SCHEMBL7256038 | 0.84 | HIF1A (0.56) | CYP2C19HIF1ACYP2D6TSHRBLM | |
| SCHEMBL20564073 | 0.83 | SLC13A5 (0.50) | CYP2C19HIF1ACYP2D6TSHRTBXA2R | |
| SCHEMBL450334 | 0.82 | TBXA2R (0.53) | CYP2C19HIF1ATBXA2RBLMLMNA | |
| SCHEMBL446707 | 0.82 | TBXA2R (0.44) | CYP2C19HIF1ATBXA2RBLMLMNA | |
| SCHEMBL28316795 | 0.79 | TBXA2R (0.41) | TBXA2RLMNAALDH1A1MEN1KMT2A | |
| SCHEMBL5149405 | 0.78 | BLM (0.46) | HIF1ABLMLMNAALDH1A1MME | |
| SCHEMBL12492687 | 0.78 | BLM (0.46) | BLMLMNAMMEMEN1KMT2A | |
| SCHEMBL11827472 | 0.77 | TBXA2R (0.44) | TSHRTBXA2RLMNAMMEMEN1 | |
| SCHEMBL2175094 | 0.77 | BLM (0.44) | BLMLMNAALDH1A1MMEMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120065195-A1 | COMPOUNDS FOR TREATING NEURODEGENERATIVE DISEASES | ARRAY BIOPHARMA INC. | 2012-03-15 | — | — | US | disclosed |
| WO-2011123674-A1 | COMPOUNDS FOR TREATING NEURODEGENERATIVE DISEASES | ARRAY BIOPHARMA INC. (US) | 2011-10-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120065195-A1 | COMPOUNDS FOR TREATING NEURODEGENERATIVE DISEASES | APP, BACE1, PSEN1 | CYP2C19 2575/4885HIF1A 2513/4885CYP2D6 2830/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.